Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 80,000 shares at $132.54 ($10.6M) on 2026-06-22, disclosed to the SEC on 2026-06-24.
Scheduled sale ($10.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |
| SYRE | SELL | 2026-05-08 | $6.0M | — | Filing → |